Dr. Richard D. Gill, President & CEO of TruTouch, said, “This financing marks completion of a significant milestone in the commercialization of the TruTouch alcohol measurement technology. TruTouch measurement offers employers, individuals, and society in general the tools to intercept alcohol intoxication before it does harm. The technology is gaining acceptance in workplace, medical, point of sale.”
TruTouch products employ an advanced intoxication detection technology that uses light to measure a subject's alcohol level without collecting bodily fluids or other invasive means. A user places a finger on a fiber optic touchpad that analyzes the alcohol concentration in the user's body and at the same time identifies the user. The device can produce accurate results in seconds, and performs built-in biometric identification to ensure test result integrity.
Unlike other technologies, TruTouch products require no user training, no disposables, no samples, and no operator assistance or supervision. TruTouch commercializes an optical sensor that accurately measures alcohol intoxication while simultaneously verifying user identity. The self-administered test detects employee alcohol abuse, allowing employers to take action before a shift begins and removing impaired employees in high-risk occupations.
Eric Janszen, Founder of iTulip, Inc. and lead of the investor syndication, said, “Our community believes that TruTouch management has demonstrated to its investor base that it can advance the company’s unique technology and patent portfolio to the next stage of growth in a growing market. We are proud to lead in the syndication of this round of financing along with Launchpad Venture Group, Verge Fund, and Jerome Capital.”
Current and future TruTouch applications include:
- Workforce Workplace Safety Systems
- Medical Diagnostic Systems
- Alcohol Point-Of-Sale Liability Reduction Systems
- Law Enforcement Systems
- Industrial Safety Systems
Join the Conversation